All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
#EHA2024: Indolent and mantle cell NHL
Catch up with our live social media coverage of indolent and mantle cell NHL, from the European Hematology Association (EHA) 2024 Hybrid Congress.
June 13—16
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to indolent and mantle cell NHL, here.
CONGRESS #EHA2024 | Late-breaking | @michaelwangmd @MDAndersonNews reports phase 3 ECHO trial of acalabrutinib (A) plus bendamustine (B) and rituximab (R) vs placebo (P) BR in untreated MCL. N=598, mFU=17 mo, mPFS=66.4 mo & 49.6 mo with ABR & PBR, resp; P=0.0160. OS was positive… pic.twitter.com/Fmlqe3JVDF
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Umberto Vitolo reports 1st results from EPCORE NHL-1 FL cycle 1 optimization (C1 OPT) cohort investigating mitigation strategies for CRS with no mandatory hospitalization in pts with R/R FL receiving epcoritamab. N=86, primary endpoint, reduction in CRS, met… pic.twitter.com/iAgDBcBrBn
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Sarit Assouline presents subgroup analysis of phase II study evaluating mosunetuzumab monotherapy in high-risk pts with heavily pre-treated R/R FL. Durable remissions and clinically meaningful survival outcomes observed, including those with POD24 (3-year PFS… pic.twitter.com/415B2bVHnB
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Tycel Phillips, MD (@LymphClinician) from @cityofhope presented an updated analysis of the phase I/II study of glofitamab for R/R #mantlecelllymphoma, demonstrating high response rates and durable responses in both BTKi-treated and -naïve pts. Majority of… pic.twitter.com/lMBPEAz4nS
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Primary analysis of the phase II ELM-2 study demonstrates deep and durable responses with odronextamab (CD20×CD3 bispecific antibody) in heavily pretreated pts with R/R FL. Primary endpoint ORR, 80%; CR rate 73%; CR correlated with favorable PFS and OS at 24… pic.twitter.com/L302fO0fGL
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 16, 2024
Enrico Tiacci, University of Perugia, presents findings from the HCL-PG04 phase II trial of obinutuzumab monotherapy and combination with vemurafenib in patients with R/R hairy cell leukemia.
▪️ Safety profile of obinutuzumab as expected, mostly grade 1 (n=26)… pic.twitter.com/jR6Hje03Y9
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
3 votes - 64 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox